Tunicamycin Mixture |
Catalog No.GC16738
One-Click Copy Product Info
|
Tunicamycin Mixture es una mezcla de antibióticos nucleósidos homólogos que inhibe la N-glycosylación y bloquea la fosfotransferasa de GlcNAc (GPT).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 11089-65-9
Sample solution is provided at 25 µL, 10mM.
Tunicamycin Mixture es una mezcla de antibióticos nucleósidos homólogos que inhibe la N-glycosylación y bloquea la fosfotransferasa de GlcNAc (GPT)[1]. Tunicamycin Mixture puede inducir estrés del retículo endoplásmico celular (ER) y conducir al bloqueo de la síntesis de DNA y a la detención de la fase G1 [2]. Tunicamycin Mixture inhibe las bacterias Gram-positivas, las levaduras, los hongos y los virus y tiene actividadanticancerígena[3].
In vitro, el pretratamiento de las células RAW264.7 con Tunicamycin Mixture (0.5μg/ml) durante 2h significativamente la producción de nitrito inducida por LPS y debilitó la expresión de iNOS y COX-2 mRNA y proteína de COX-2 [4]. Tunicamycin Mixture (1-20μg/ml) trató las células PC-3 de cáncer de próstata durante 24-96h, la viabilidad celular reducida dependiente de la dosis, bloqueó la formación de N-glycosylation en proteínas y el estrés del endoplasmic reticulum inducido [5] .
In vivo, Tunicamycin Mixture tratada con ratones (1mg/kg) a través de inyección intraperitoneal aumentó significativamente la acumulación de triglicéridos hepáticos, inhibió la secreción de lipoproteína hepática y redujo los niveles de glucosa en sangre y el contenido de glucógeno hepático[6]. La administración de Tunicamycin mixture (2μg) a través de la administración intratraqueal en un modelo de asma neutrófila( ratones OVALPS-OVA) aumentó los niveles de expresión de proteínas de los marcadores de estrés del retículo endoplasmático y las citoquinas inflamatorias, lo que llevó a un fenotipo de asma más grave en los ratones[7].
References:
[1] Hsu J L, Chiang P C, Guh J H. Tunicamycin induces resistance to camptothecin and etoposide in human hepatocellular carcinoma cells: role of cell-cycle arrest and GRP78[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2009, 380: 373-382.
[2] Han C, Jin L, Mei Y, et al. Endoplasmic reticulum stress inhibits cell cycle progression via induction of p27 in melanoma cells[J]. Cellular signalling, 2013, 25(1): 144-149.
[3] Pałasz A, Cież D. In search of uracil derivatives as bioactive agents. Uracils and fused uracils: Synthesis, biological activity and applications[J]. European journal of medicinal chemistry, 2015, 97: 582-611.
[4] Kim S Y, Hwang J S, Han I O. Tunicamycin inhibits Toll-like receptor-activated inflammation in RAW264. 7 cells by suppression of NF-κB and c-Jun activity via a mechanism that is independent of ER-stress and N-glycosylation[J]. European journal of pharmacology, 2013, 721(1-3): 294-300.
[5] Guha P, Kaptan E, Gade P, et al. Tunicamycin induced endoplasmic reticulum stress promotes apoptosis of prostate cancer cells by activating mTORC1[J]. Oncotarget, 2017, 8(40): 68191.
[6] Feng B, Huang X, Jiang D, et al. Endoplasmic reticulum stress inducer tunicamycin alters hepatic energy homeostasis in mice[J]. International journal of molecular sciences, 2017, 18(8): 1710.
[7]Guo Q, Li H, Liu J, et al. Tunicamycin aggravates endoplasmic reticulum stress and airway inflammation via PERK-ATF4-CHOP signaling in a murine model of neutrophilic asthma[J]. Journal of Asthma, 2017, 54(2): 125-133.
| Experimentos celulares [1]: | |
Líneas celulares | Células RAW264.7 |
Método de preparación | Las células RAW264.7 fueron pretratadas con 0.5μg/ml de Tunicamycin Mixture durante 2h y luego se incubaron con LPS durante 18h. |
Condiciones de reacción | 0.5μg/ml; 2 h |
Áreas de aplicación | Tunicamycin Mixture redujo significativamente la producción/liberación de nitrito inducida por LPS y atentó iNOS y COX-2 mRNA y la expresión de proteínas. |
| Experimentos con animales [2]: | |
Modelos animales | C57BL/6 ratones macho |
Método de preparación | Los ratones se dividieron aleatoriamente en 2 grupos de acuerdo con un peso corporal promedio similar y el nivel de glucosa en sangre. Un grupo fue inyectado por vía intraperitoneal con 1mg/kg de Tunicamycin Mixture o vehículo. El peso corporal y el nivel de glucosa en sangre en estado alimentado se midieron 24 horas después de la inyección. Más tarde, los ratones fueron sacrificados con dióxido de carbono, seguido de dislocación cervical. |
Forma de dosificación | 1mg/kg；i.p. |
Áreas de aplicación | El tratamiento de Tunicamycin Mixture durante 24 horas significativamente la acumulación de triglicéridos hepáticos, inhibió la secreción de lipoproteínas hepáticas y redujo los niveles de azúcar en la sangre y el contenido de glucógeno hepático. |
References: | |
| Cas No. | 11089-65-9 | SDF | |
| Formula | C39H64N4O16 (for Tunicamycin VII) | M.Wt | 845.0 |
| Solubility | DMF: 20 mg/ml DMSO: 20 mg/ml DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.1834 mL | 5.9172 mL | 11.8343 mL |
| 5 mM | 236.7 μL | 1.1834 mL | 2.3669 mL |
| 10 mM | 118.3 μL | 591.7 μL | 1.1834 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Tibial and growth plate images. (A) Representative images of tibia. (B) Safranin O/fast green staining of tibial growth plate in the control, MPs + SAL, MPs, and MPs + TM groups.
The ER-stress agonist group was administered with MPs at 2.0 mg/kg.bw/d by gavage, followed by intraperitoneal injection of TM(GlpBio) at 100 mg/kg.bw/d after 30 min.
Environmental Toxicology (2024). PMID: 38440912 IF: 4.5003 -
Related Biological Data
Acacetin decreases the expression of lipid synthesis and ferroptosis-related genes, reduces iron overload, and inhibits oxidative stress. (A). Hepatic iron content. (B). The lipid peroxidation product MDA was tested. (C) Hepatic GSH was measured.
The decrease of intracellular TG and mRNA levels of genes related to lipid synthesis caused by acacetin was significantly reversed by erastin (5 mM) and TU (1 mM) (GlpBio)
Biochem Bioph Res Co 640 (2023): 183-191. PMID: 36516527 IF: 3.322 -
Related Biological Data
TREM1 knockdown reduces inflammation and apoptosis of NPCs through inhibiting ERS. (A) The levels of inflammatory factors were measured with ELISA kits. The influence of MPLA and tunicamycin on apoptosis of the NPCs was assessed using
Tunicamycin, an endoplasmic reticulum stress (ERS) agonist, was purchased from Glpbio Technology, Inc. and NPCs were treated with tunicamycin at a concentration at 5 µg/ml (20).
Exp Ther Med 24.4 (2022): 1-11. PMID: 36160910 IF: 2.7511
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)